Search Results - "Nyvang, Gitte‐Bettina"

Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial by Mirza, Mansoor Raza, MD, Åvall Lundqvist, Elisabeth, PhD, Birrer, Michael J, Prof, dePont Christensen, Rene, PhD, Nyvang, Gitte-Bettina, MD, Malander, Susanne, PhD, Anttila, Maarit, PhD, Werner, Theresa L, MD, Lund, Bente, MD, Lindahl, Gabriel, MD, Hietanen, Sakari, PhD, Peen, Ulla, MD, Dimoula, Maria, MD, Roed, Henrik, DMSci, Ør Knudsen, Anja, MD, Staff, Synnöve, PhD, Krog Vistisen, Anders, MD, Bjørge, Line, Prof, Mäenpää, Johanna U, Prof

“…SummaryBackgroundPlatinum-based chemotherapy is the foundation of treatment for platinum-sensitive recurrent ovarian cancer, but has substantial toxicity…”
Get full text

Circulating cell‐free HPV DNA is a strong marker for disease severity in cervical cancer by Bønløkke, Sara, Steiniche, Torben, Sorensen, Boe Sandahl, Nyvang, Gitte‐Bettina, Lindegaard, Jacob Christian, Blaakær, Jan, Bertelsen, Jesper, Fuglsang, Katrine, Strube, Mikael Lenz, Lenz, Suzan, Stougaard, Magnus

“…For cervical cancer (CC), circulating cell‐free HPV DNA (ccfHPV) may establish disease severity. Furthermore, HPV integration has been correlated to viral load…”
Get full text

The Diagnostic Value of Circulating Cell-Free HPV DNA in Plasma from Cervical Cancer Patients by Bønløkke, Sara, Stougaard, Magnus, Sorensen, Boe Sandahl, Booth, Berit Bargum, Høgdall, Estrid, Nyvang, Gitte-Bettina, Lindegaard, Jacob Christian, Blaakær, Jan, Bertelsen, Jesper, Fuglsang, Katrine, Strube, Mikael Lenz, Lenz, Suzan, Steiniche, Torben

“…Circulating cell-free HPV DNA (ccfHPV DNA) may serve as a marker for cervical cancer. In this study, we used digital droplet PCR (ddPCR) to detect and quantify…”
Get full text

From point A to the sculpted pear: MR image guidance significantly improves tumour dose and sparing of organs at risk in brachytherapy of cervical cancer by Tanderup, Kari, Nielsen, Søren Kynde, Nyvang, Gitte-Bettina, Pedersen, Erik Morre, Røhl, Lisbeth, Aagaard, Torben, Fokdal, Lars, Lindegaard, Jacob Christian

“…Abstract Background and purpose Brachytherapy in locally advanced cervical cancer is still widely based on 2D standard dose planning, although 3D image…”
Get full text

Trends in gynecologic cancer among elderly women in Denmark, 1980-2012 by Ør Knudsen, Anja, Schledermann, Doris, Nyvang, Gitte-Bettina, Mogensen, Ole, Herrstedt, Jørn

“…The aim of this analysis was to describe trends in incidence, mortality, prevalence, and survival in Danish women with gynecologic cancer from 1980-2012…”
Get more information

1446: MARGARITA: MRLinac Boost for Gynecological Cancers if brachytherapy is not feasible. Initial results by van Lier, Astrid, Bernchou, Uffe, van der Leij, Femke, Knudsen, Anja Ør, Hes, Jochem, Nyvang, Gitte-Bettina, Zweemer, Ronald, van Breugel, Eline Groot, Hazell, Irene, Schytte, Tine, Bertelsen, Anders Smedegaar, Jürgenliemk-Schulz, Ina

Get full text

Efficacy and safety of alpelisib plus olaparib versus chemotherapy among patients with platinum-resistant or refractory high-grade serous ovarian cancer without BRCA mutation: Primary analysis of the EPIK-O trial by Konstantinopoulos, Panagiotis, Kim, Jae-Weon, Freyer, Gilles, Lee, Jung-Yun, Gaba, Lydia, Grisham, Rachel, Colombo, Nicoletta, Wu, Xiaohua, Sehouli, Jalid, Cruz, Felipe, Cibula, David, Monk, Bradley, Nyvang, Gitte-Bettina, Friedlander, Michael, Lorusso, Domenica, Van Nieuwenhuysen, Els, Glasspool, Rosalind, Marth, Christian, Hinson, Patsy, Zuradelli, Monica, Wang, Craig, Su, Faye, Miller, Michelle, Matulonis, Ursula, González-Martín, Antonio

Get full text

Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial by Harter, Philipp, Trillsch, Fabian, Okamoto, Aikou, Reuss, Alexander, Kim, Jae-Weon, Rubio-Pérez, Maria Jesús, Vardar, Mehmet Ali, Scambia, Giovanni, Tredan, Olivier, Nyvang, Gitte-Bettina, Colombo, Nicoletta, Chudecka-Głaz, Anita M., Grimm, Christoph, Lheureux, Stephanie, Van Nieuwenhuysen, Els, Heitz, Florian, Wenham, Robert M., Ushijima, Kimio, Day, Emily, Aghajanian, Carol

“…LBA5506 Background: Olaparib (ola) maintenance (mtx) improved outcomes in pts with newly diagnosed AOC and a BRCAm (DiSilvestro J Clin Oncol 2023;41:609–17) or…”
Get full text

A randomized Phase III trial of durvalumab with chemotherapy and bevacizumab, followed by maintenance durvalumab, bevacizumab and olaparib in newly diagnosed advanced ovarian cancer (DUO-O): Updated trial endpoint and inclusion of China cohort (329) by Okamoto, Aikou, Kim, Jae-Weon, Yin, Rutie, Trillsch, Fabian, Reuss, Alexander, Aghajanian, Carol, Rubio-Pérez, Maria Jesús, Vardar, Mehmet Ali, Scambia, Giovanni, Floquet, Anne, Nyvang, Gitte-Bettina, Colombo, Nicoletta, Bidzinski, Mariusz, Marth, Christian, Lheureux, Stéphanie, Van Nieuwenhuysen, Els, Rugman, Paul, Wessen, Jonathan, Harter, Philipp

Get full text

PP022 Establishment of an open standard for identification of HRD and patient susceptibility to PARPi by Korsholm, Lea Milling, Kjeldsen, Maj, Perino, Lorenzo, Mariani, Luca, Nyvang, Gitte-Bettina, Kristensen, Elisabeth, Bagger, Frederik Otzen, Mirza, Mansoor Raza, Rossing, Maria

Get full text

Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer: A randomized controlled chemotherapy-free study—NSGO-AVANOVA2/ENGOT-OV24 by Mirza, Mansoor Raza, Avall-Lundqvist, Elisabeth, Birrer, Michael J., Christensen, Rene dePont, Nyvang, Gitte-Bettina, Malander, Susanne, Anttila, Maarit, Werner, Theresa Louise, Lund, Bente, Lindahl, Gabriel, Hietanen, Sakari, Peen, Ulla, Dimoula, Maria, Roed, Henrik, Knudsen, Anja Ør, Boufercha, Louisa, Staff, Synnove, Krog Vistisen, Anders, Bjørge, Line, Maenpaa, Johanna Unelma

“…Abstract only 5505 Background: Standard treatment of platinum-sensitive recurrent ovarian cancer (PSROC) is platinum based combination chemotherapy ±…”
Get full text

DUO-O: A randomized phase III trial of durvalumab (durva) in combination with chemotherapy and bevacizumab (bev), followed by maintenance durva, bev and olaparib (olap), in newly diagnosed advanced ovarian cancer patients by Harter, Philipp, Bidziński, Mariusz, Colombo, Nicoletta, Floquet, Anne, Rubio Pérez, Maria Jesús, Kim, Jae-Weon, Lheureux, Stephanie, Marth, Christian, Nyvang, Gitte-Bettina, Okamoto, Aikou, Reuss, Alexander, Scambia, Giovanni, Trillsch, Fabian, Vardar, Mehmet Ali, Van Nieuwenhuysen, Els, Lichfield, Jasmine, Rugman, Paul, Twumasi-Ankrah, Philip, Aghajanian, Carol

“…Abstract only TPS5598 Background: Ovarian cancer (OC) is the leading cause of death from gynecologic cancers in US women. Despite high response rates to…”
Get full text